Our aspiration is to always supply high-quality, safe products and services that help to positively impact patient incomes and improve health economics. We are continuously investing in our operations and staff to ensure our staff are trained and educated in the most important quality standards and requirements to ensure all employees carry out high-quality work.
Our certificates, as with other regulatory approvals, are proof of our commitment to quality and our commitment to maintaining a high level of quality for our products and processes.
As the Magle Group DSM portfolio grows we are committed to investing in performing clinical studies and post-market clinical studies in order to generate more data about our products.
We undertake post market surveillance to monitor the safety of a pharmaceutical drug or medical device that we release on to the market to ensure there are no adverse patient or professional health worker events to monitor the safety of our products. We actively survey users to gather vital data and track trends and feedback to further improve our products.
|Dsm-Tpce (Transpulmonary |
Chemoembolization) of Non-Small Cell
Lung Cancer (NSCLC) in the Left Hilar
|Intrahepatic Cholangiocarcinoma (ICC) |
Treated with DSM-TACE
|Dsm-Tace of Unresectable Perihilar |